For Investors

Medicine advances when relationship becomes explicit. Timing is the operating system. Coherence is the outcome. Chasing fragmented signals can only lead to delayed insight, escalating complexity, and care that reacts after the drift has already become disease.

A timing-first, relationship-centered approach changes the unit of medicine. It treats the body as a coordinated system that can be measured as coordination: who leads, who follows, what locks together, what slips, and how fast the system returns to coherence after perturbation. That creates earlier visibility, clearer trend direction, and a measurable sense of protocol response—so interventions can be paced, personalized, and validated over time. Patients win because drift is seen before collapse and progress becomes tangible. Clinicians win because decisions gain structure beyond trial-and-error and follow-up becomes more efficient and defensible. Payers and systems win because upstream clarity reduces downstream intensity—fewer preventable crashes, fewer repeated workups, fewer chronic spirals that become lifelong cost centers. Timing and relationship are the keynote for a new era because they make medicine more coherent for everyone involved: fewer surprises, better targeting, faster learning, and outcomes that improve because the system is finally measured as a system.

 

Fieldflux is building into that era through two interconnected systems grounded in the same fusion mathematics. QPCI™ (Quantum Phase-Coherence Imaging) is designed to use advanced sensing—EEG/ECG, autonomic and metabolic inputs, and other high-resolution modalities—to compute a family of metrics that describe how well an individual’s whole system is functioning. The decisive innovation is not the sensors themselves. Measuring signals is an engineering challenge that yields to time, capital, and execution. The defining leap is synthetic interpretation: turning distinct measurements into a single coherent view of state. That fusion—done correctly, repeatably, and safely—is where the value concentrates.

Membrane: Health is the proof of that claim. The iOS app is already built and running in closed beta, with a planned public release in Q2 2026. From the outside, it stands on its own as an immediately useful and unique product for everyday people who already use health trackers, and for professionals—clinicians, coaches, trainers—who want a clearer way to interpret and understand a client’s active state. Inside, Membrane carries an underlying secret: it demonstrates the fusion engine in operation today. Using a dataset that is already captured, Membrane takes distinct health metrics and gathers them into a single synthetic view of an individual’s health state. The mathematics used to fuse HealthKit-derived data is essentially the same mathematics intended for QPCI—making Membrane both a standalone product and a working testimonial that the hardest part of QPCI is already real, stable, and in use.

This changes the investment story. The hard part is already done: the fusion engine—the vital piece that makes synthesis possible—is functionally complete and stable. The work now is translation and scale: expand instrumentation pathways, accelerate prototype development, run pilots that produce decisive evidence, and build the distribution and professional workflows that carry this timing-first model into practice.

 

Fieldflux’s job is to keep the platform rigorous, keep outputs defensible, and build products that make relationship measurable in the real world. Investment partners help turn a proven engine into a deployed standard—funding the team, prototypes, pilots, and partnerships needed to bring coherence-based medicine to market.

Fieldflux is opening a limited set of conversations with investors who want to help build this next layer of medicine. If there’s alignment—on rigor, on impact, and on the belief that timing and relationship belong at the center of care—reach out. We can share current product status, roadmap, pilot plans, and diligence materials under NDA, and explore how to collaborate on turning a validated engine into a deployed standard.